Travere Therapeutics, Inc. (TVTX)
$51.80-0.42%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4.8B
- Beta
- 1.14
- P/E (TTM)
- -115.11
- Short % float
- 14.01%
- Days to cover
- 7.2
- SI change
- -2.3%
- 1W
- -7.47%
- 1M
- -21.26%
- vs SPY 1W
- -7.33%
- vs SPY 1M
- -23.77%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 34
- VALUE
- 7
- GROWTH
- 20
- GARP
- 70
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-33.5%
REV YoY-
ROE-55.8%
EPS YoY-
ROA-5.4%
GROSS94
OP-7
NET-7
[VALUATION]
P/E TTM-115.11
P/E FWD18.54
SECTOR PE20.34
INDUSTRY PE13.84
P/B197.46
P/FCF-
EV/EBITDA920.08
EV/EBIT-
PEG0.88
FCF YIELD-
RISK
INT COV-
D/E2515.72
ALTMAN Z-
CURR RATIO4.05
ND/EBITDA-
BETA1.14
Company news
FAQ
- What is LOPJLB’s current signal on TVTX?
- LOPJLB’s latest quantitative signal on Travere Therapeutics, Inc. (TVTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TVTX in?
- Travere Therapeutics, Inc. (TVTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Travere Therapeutics, Inc. (TVTX) do?
- Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 t…